Skip to main content
. Author manuscript; available in PMC: 2012 May 1.
Published in final edited form as: Circ Cardiovasc Qual Outcomes. 2011 Apr 12;4(3):328–336. doi: 10.1161/CIRCOUTCOMES.110.957720

Figure 1.

Figure 1

Changes in LDL levels in women (A) and men (B) as stratified by randomization treatment group from baseline to 30-days, 4-, 8-, 16-months, and final visit. A greater percent reduction in LDL was observed in the high-dose atorvastatin group as compared to the standard-dose pravastatin group at all follow-up time points (all p<0.0001). Changes in hs-CRP levels in women (C) and men (D) as stratified by randomization treatment group from baseline to 30-days, 4-month, and final visit. The hs-CRP levels were significantly lower in the high-dose atorvastatin than standard-dose pravastatin arm at all follow-up time points (all p≤0.003).